Diamonds in the Rough
Cross-referencing fundamental value against technical exhaustion to isolate beaten-down XBI constituents that screen cheap and oversold. The bottom-right quadrant — high earnings yield, low RSI — is the prime hunting ground, especially where money flow (MFI) shows quiet accumulation despite the falling price.
Educational screen, not investment advice. “Diamond” classification is a mechanical valuation-vs-RSI split around the cohort median earnings yield and an RSI of 50.
Alpha Quadrant — Valuation × Technical Exhaustion
X = earnings yield (cheaper right) · Y = RSI 14 (more oversold lower) · bubble = market cap · color = money flow.
Diamond Candidates
Ranked by a composite of earnings yield, ROIC, oversold RSI, recent weakness, and improving money flow.
| # | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | NRIX | Nurix Therapeutics, Inc. Common stock | 67.9 | 29.83% | 0.29 | 27 | -34.60% | 35 | safe |
| 2 | RIGL | Rigel Pharmaceuticals Inc. (New) | 62.1 | 9.49% | 0.69 | 44 | -5.42% | 53 | safe |
| 3 | HALO | Halozyme Therapeutics, Inc. | 61.5 | 5.30% | 0.50 | 27 | -15.28% | 28 | safe |
| 4 | VCYT | Veracyte, Inc. | 60.6 | 5.64% | 0.24 | 28 | -43.89% | 41 | safe |
| 5 | IRWD | Ironwood Pharmaceuticals, Inc. - Class A | 58.0 | 24.25% | 1.30 | 75 | +33.06% | 82 | distress |
| 6 | ABUS | Arbutus Biopharma Corporation Common Stock | 56.5 | 24.39% | 0.55 | 49 | -3.31% | 57 | safe |
| 7 | ALNY | Alnylam Pharmaceuticals, Inc. | 55.5 | 4.58% | 0.27 | 35 | -28.24% | 34 | safe |
| 8 | ABBV | ABBVIE INC. | 50.9 | 3.55% | 65.88 | 63 | +2.34% | 61 | safe |
| 9 | EXEL | Exelixis Inc | 47.4 | 6.07% | 1.01 | 59 | +11.85% | 59 | safe |
| 10 | PTGX | Protagonist Therapeutics, Inc | 45.7 | 4.01% | 0.31 | 39 | -4.22% | 49 | safe |
| 11 | NBIX | Neurocrine Biosciences Inc | 44.0 | 5.27% | 0.77 | 64 | +21.96% | 68 | safe |
| 12 | PGEN | Precigen, Inc. Common Stock | 42.8 | 1.97% | 0.22 | 34 | -37.89% | 47 | distress |
| 13 | ADMA | ADMA Biologics, Inc. | 42.0 | 7.51% | 0.43 | 71 | +29.06% | 50 | safe |
| 14 | KRYS | Krystal Biotech, Inc. Common Stock | 41.1 | 2.65% | 0.20 | 43 | -8.33% | 56 | safe |
| 15 | ACAD | Acadia Pharmaceuticals Inc. | 41.1 | 4.19% | 0.13 | 42 | -3.75% | 49 | safe |
Short-Squeeze Watch
Constituents with the highest composite squeeze score — heavy short interest meeting price support.
| # | |||||||
|---|---|---|---|---|---|---|---|
| 1 | SPRY | ARS Pharmaceuticals, Inc. Common Stock | 95.1 | 38.77% | 11.09 | -2.51% | critical |
| 2 | KOD | Kodiak Sciences Inc Common Stock | 88.5 | 27.42% | 9.34 | +36.77% | critical |
| 3 | SMMT | Summit Therapeutics Inc. Common Stock | 88.5 | 30.52% | 9.40 | -6.23% | critical |
| 4 | IBRX | ImmunityBio, Inc. Common Stock | 88.5 | 31.99% | 10.77 | -40.98% | critical |
| 5 | TNGX | Tango Therapeutics, Inc. | 86.9 | 34.35% | 9.73 | +14.53% | critical |
| 6 | ZBIO | Zenas BioPharma, Inc. Common Stock | 86.2 | 36.44% | 24.08 | +12.22% | critical |
| 7 | ACHV | Achieve Life Sciences, Inc. | 84.1 | 28.62% | 13.58 | -5.90% | critical |
| 8 | OLMA | Olema Pharmaceuticals, Inc. Common Stock | 83.7 | 27.10% | 11.86 | +10.53% | critical |
| 9 | TYRA | Tyra Biosciences, Inc. Common Stock | 83.5 | 27.59% | 15.28 | +6.18% | critical |
| 10 | IMVT | Immunovant, Inc. Common Stock | 82.7 | 21.40% | 15.26 | +21.94% | critical |
| 11 | NGNE | Neurogene, Inc. Common Stock | 82.7 | 44.17% | 16.95 | +7.07% | critical |
| 12 | INBX | Inhibrx Biosciences, Inc. Common Stock | 82.4 | 35.17% | 10.00 | -4.91% | critical |
Market cap, valuation, and short-interest metrics are joined to the latest XBI holdings snapshot; each ticker links to its full quote and analysis page.